Nxera Pharma Co Ltd (SOLTF)
9.816
+0.04
(+0.37%)
USD |
OTCM |
May 10, 16:00
Nxera Pharma Revenue (Quarterly): 31.07M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 31.07M |
| December 31, 2023 | 49.39M |
| September 30, 2023 | 23.04M |
| June 30, 2023 | 8.767M |
| March 31, 2023 | 7.139M |
| December 31, 2022 | 49.14M |
| September 30, 2022 | 44.77M |
| June 30, 2022 | 10.33M |
| March 31, 2022 | 9.632M |
| December 31, 2021 | 124.23M |
| September 30, 2021 | 4.243M |
| June 30, 2021 | 17.50M |
| March 31, 2021 | 11.40M |
| December 31, 2020 | 42.12M |
| September 30, 2020 | 18.16M |
| June 30, 2020 | 12.58M |
| March 31, 2020 | 10.67M |
| December 31, 2019 | 17.99M |
| September 30, 2019 | 25.30M |
| June 30, 2019 | 17.46M |
| March 31, 2019 | 28.48M |
| December 31, 2018 | 9.482M |
| September 30, 2018 | 8.694M |
| June 30, 2018 | 7.656M |
| March 31, 2018 | 6.255M |
| Date | Value |
|---|---|
| December 31, 2017 | 8.527M |
| September 30, 2017 | 22.80M |
| June 30, 2017 | 25.06M |
| March 31, 2017 | 15.68M |
| December 31, 2016 | 11.72M |
| September 30, 2016 | 7.386M |
| June 30, 2016 | 139.64M |
| March 31, 2016 | 3.558M |
| December 31, 2015 | 42.81M |
| September 30, 2015 | 16.08M |
| June 30, 2015 | 4.740M |
| March 31, 2015 | 22.83M |
| December 31, 2014 | 3.366M |
| September 30, 2014 | 3.165M |
| June 30, 2014 | 2.310M |
| March 31, 2014 | 2.253M |
| December 31, 2013 | 2.471M |
| September 30, 2013 | 15.37M |
| June 30, 2013 | 0.7105M |
| March 31, 2013 | 1.059M |
| December 31, 2012 | 7.921M |
| September 30, 2012 | 12.90M |
| June 30, 2012 | 2.544M |
| March 31, 2012 | 0.3561M |
| December 31, 2011 | 0.3813M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
4.243M
Minimum
Sep 2021
124.23M
Maximum
Dec 2021
26.75M
Average
17.75M
Median
Revenue (Quarterly) Benchmarks
| Takeda Pharmaceutical Co Ltd | 7.081B |
| PeptiDream Inc | 41.78M |
| Healios KK | 0.0474M |
| AnGes Inc | 0.3408M |
| SanBio Co Ltd | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -22.11M |
| Total Expenses (Quarterly) | 51.79M |
| EPS Diluted (Quarterly) | -0.2471 |
| Enterprise Value | 1.018B |
| Gross Profit Margin (Quarterly) | 74.17% |
| Profit Margin (Quarterly) | -71.16% |
| Earnings Yield | -7.48% |
| Normalized Earnings Yield | -7.479 |